GH
Guardant Health Inc

4,763
Loading...
Loading...
News
all
press releases
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Zacks·7d ago
News Placeholder
More News
News Placeholder
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Zacks·1mo ago
News Placeholder
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Zacks·2mo ago
News Placeholder
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Zacks·2mo ago
News Placeholder
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·2mo ago
News Placeholder
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Tempus AI Taps Growing ICI Market With New xM Assay
TEM launches xM, a liquid biopsy assay to monitor real-time response to ICI therapy in advanced solid tumors.
Zacks·2mo ago
News Placeholder
Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release
TEM's revenue and gross profit are climbing fast as new AI tools and data services boost margins ahead of Q2 earnings.
Zacks·3mo ago
News Placeholder
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Zacks·4mo ago
News Placeholder
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
Zacks·4mo ago

Latest GH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.